// App-Quantinova.ai

TPS5097 : c15-148: Phase I/II trial of concurrent chemohormonal therapy using enzalutamide and cabazitaxel in patients with metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Julie Nicole Graff

Principal Investigators

  • Tomasz M. Beer

  • Joshi J. Alumkal

  • Dustin Kreitner

  • Delia Petreaca

  • George V. Thomas

  • Heather H. Cheng

Medical Centers

  • Portland VA Health Care System and Knight Cancer Institute, Oregon Health & Science University, Portland, OR

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Knight Cancer Institute, Portland, OR

  • University of Washington, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Cabazitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02522715

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved